Schedule tool
Titration Schedule Builder
Generate a research-stage stepwise titration plan for any incretin-class peptide — or any peptide on the site. Set your starting dose, target maintenance, step size and step duration; the builder lays out the week-by-week schedule, totals the cumulative peptide required, and surfaces the right bloodwork checkpoints for the peptide class.
Inputs
Modelled on the published Semaglutide STEP trial: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg weekly, stepping every 4 weeks until the maintenance dose.
Filtered to the Metabolic / GLP-1 class — stepwise titration matters most for incretin-receptor agonists.
Common: 3, 5, 10, 15 mg
Summary
Titration phase
20 wk
Maintenance phase
12 wk
Total duration
32 wk
Total peptide
53.8 mg
Vials
18 × 3 mg
Weekly admins
1
Dose-over-time stepped profile
Calculations run entirely in your browser. Schedule patterns are research-stage models, not clinical recommendations.
Week-by-week schedule
Click any row to open the Dosage Calculator pre-filled for that step.
| Weeks | Phase | Dose / admin | Weekly total | Cumulative mg | |
|---|---|---|---|---|---|
| Weeks 1–4 | titration | 250 mcg | 0.25 mg | 1.0 mg | Open dosage |
| Weeks 5–8 | titration | 750 mcg | 0.75 mg | 4.0 mg | Open dosage |
| Weeks 9–12 | titration | 1.25 mg | 1.25 mg | 9.0 mg | Open dosage |
| Weeks 13–16 | titration | 1.75 mg | 1.75 mg | 16.0 mg | Open dosage |
| Weeks 17–20 | titration | 2.25 mg | 2.25 mg | 25.0 mg | Open dosage |
| Weeks 21–32 | maintenance | 2.40 mg | 2.40 mg | 53.8 mg | Open dosage |
Suggested bloodwork checkpoints
Markers below are typical for the Metabolic / GLP-1 class. Use as a starting point, not a clinical prescription.
Checkpoint 1
Week 1
Baseline panel before week 1
Checkpoint 2
Week 4
Tolerability check after the first titration step
Checkpoint 3
Week 16
Mid-protocol panel at the start of maintenance
Checkpoint 4
Week 32
End-of-cycle panel two weeks after the final administration
Why titration matters for GLP-1 / GIP / glucagon agonists
Every published research-stage protocol for Semaglutide, Tirzepatide and Retatrutide uses a multi-step dose escalation rather than starting at the maintenance level. The stated rationale is identical across the literature: stepping the dose lets the gut adapt to slowed gastric emptying and reduces the rate of nausea, dyspepsia and vomiting — the dominant tolerability-failure modes at the therapeutic plateau.
The builder above implements the three canonical trial ramps as one-click presets, plus conservative and aggressive variants. The custom mode lets you specify every parameter independently — useful when your research design calls for a non-standard target or step size.
How the maths works
Starting at the start dose, the builder adds stepMcg every stepWeeks weeks until the running dose reaches the target maintenance level. The maintenance phase then runs at the target level for the duration you choose. Cumulative peptide is summed across both phases as dose × administrations-per-week (taken from the peptide's default frequency) times the number of weeks at that dose.
Bloodwork checkpoints
Suggested markers are tied to the peptide class:
- Metabolic / GLP-1: HbA1c, fasting glucose, lipid panel, weight, blood pressure, liver enzymes.
- Growth Hormone: IGF-1, fasting glucose, lipid panel, thyroid panel.
- Healing & Repair: hs-CRP, full blood count, fibrinogen.
- Mitochondrial: fasting glucose, lactate, lipid panel.
- Longevity: hs-CRP, IGF-1, lipid panel, fasting glucose.
Click any week to open the dosage calculator
Every row in the schedule table includes an “Open dosage” link that takes you to the Dosage Calculator pre-filled with that week's dose, the selected peptide, and the chosen vial size. Use it to get the exact draw volume and syringe-tick count for any step.
Related tools
- Dosage Calculator — for the per-administration draw volume.
- Cost & Supply Planner — to budget the cumulative spend across the titration arc.
- Half-Life Calculator — to visualise the steady-state concentration that the maintenance dose produces.
- Protocol Simulator — for non-incretin protocols where the phase shape matters more than a stepwise ramp.